摘要
目的:了解多西紫杉醇加表阿霉素对局部晚期乳腺癌患者进行新辅助化疗的疗效及不良反应。方法:对我院治疗的63例均采用多西紫杉醇加表阿霉素(DE方案:多西紫杉醇75 mg/m2d1,表阿霉素75 mg/m2d1)化疗的局部晚期乳腺癌患进行回顾性分析,每位患者进行2-4疗程的化疗,结束后评估疗效及不良反应。结果:总有效率(CR+PR)为68.3%,完全缓解(CR)8例,部分缓解(PR)35例,无变化(SD)13例,进展(PD)7例。术后中位随访24个月,死亡6例,复发及转移13例,健在44例。结论:多西紫杉醇联合表阿霉素术前化疗可以使患者降期,使原发灶缩小,以增加手术机会,提高生存率。
Objective： To investigate the efficacy and toxicity of docetaxel-epirubicin regimen in treating advanced breast cancer.Methods： A retrospective analysis was taken on a total of 63 patiens with advanced breast cancer treated with docetaxel-epirubicin（docetaxel was administered at 75 mg/m2iv d1 and epirubicin was administered at 75 mg/m2iv d1）.The treatment was repeated every 21 days at lesat for 2-4 cycles.The efficacy and toxicity were evaluated at the end of each cycle.Results： The total effective rate（CR＋PR）was 68.3%,8 cases received CR,35 PR,13 SD and 7 PD.24 months was median time of follow-up,6 cases died,13 cases relapsed and metastasis,44 cases alived.Conclusion： docetaxel-epirubicin regimen as neoadjuvant chemotherapy can shrink tumor size,increase the operation chance and improve the survival rate.
出处
《现代肿瘤医学》
CAS
2011年第8期1554-1556,共3页
Journal of Modern Oncology
